Liquid biopsy in lung cancer management

Liquid biopsy is a promising tool for a better cancer management and currently opens perspectives for several clinical applications, such as detection of mutations when the analysis from tissue is not available, monitoring tumor mutational burden and prediction of targeted therapy response. These ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Irofei Zamfir, Maria-Anca, Buburuzan, Laura, Hudiţă, Ariana, Gălăţeanu, Bianca, Ginghină, Octav, Ion, Daniel, Motaş, Natalia, Ardeleanu, Carmen Maria, Costache, Marieta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593132/
https://www.ncbi.nlm.nih.gov/pubmed/36074665
http://dx.doi.org/10.47162/RJME.63.1.02
_version_ 1784815090894110720
author Irofei Zamfir, Maria-Anca
Buburuzan, Laura
Hudiţă, Ariana
Gălăţeanu, Bianca
Ginghină, Octav
Ion, Daniel
Motaş, Natalia
Ardeleanu, Carmen Maria
Costache, Marieta
author_facet Irofei Zamfir, Maria-Anca
Buburuzan, Laura
Hudiţă, Ariana
Gălăţeanu, Bianca
Ginghină, Octav
Ion, Daniel
Motaş, Natalia
Ardeleanu, Carmen Maria
Costache, Marieta
author_sort Irofei Zamfir, Maria-Anca
collection PubMed
description Liquid biopsy is a promising tool for a better cancer management and currently opens perspectives for several clinical applications, such as detection of mutations when the analysis from tissue is not available, monitoring tumor mutational burden and prediction of targeted therapy response. These characteristics validate liquid biopsy analysis as a strong cancer biomarkers source with high potential for improving cancer patient’s evolution. Compared to classical biopsy, liquid biopsy is a minimal invasive procedure, and it allows the real-time monitoring of treatment response. Considering that lung cancer is the most common cause of cancer-associated death worldwide and that only 15–19% of the lung cancer patients survive five years after diagnosis, there is an important interest in improving its management. Like in other types of solid cancers, lung cancer could benefit from liquid biopsy through a simple peripheral blood sample as tumor-related biomarkers, such as circulating tumor cells (CTCs), cell-free nucleic acids (cfNA) [cell-free ribonucleic acid (cfRNA) and cell-free deoxyribonucleic acid (cfDNA)], exosomes and tumor-educated platelets (TEPs) may shed into circulation because of necrosis or in an active manner. More, the detection and analysis of these biomarkers could lead to a better understanding of oncological diseases like lung cancer. The better the tumor profile is established; the better management is possible. However, this approach has currently some limitations, such as low cfNA concentration or low count of CTCs that might be overcome by improving the actual methods and technologies.
format Online
Article
Text
id pubmed-9593132
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest
record_format MEDLINE/PubMed
spelling pubmed-95931322022-11-14 Liquid biopsy in lung cancer management Irofei Zamfir, Maria-Anca Buburuzan, Laura Hudiţă, Ariana Gălăţeanu, Bianca Ginghină, Octav Ion, Daniel Motaş, Natalia Ardeleanu, Carmen Maria Costache, Marieta Rom J Morphol Embryol Review Liquid biopsy is a promising tool for a better cancer management and currently opens perspectives for several clinical applications, such as detection of mutations when the analysis from tissue is not available, monitoring tumor mutational burden and prediction of targeted therapy response. These characteristics validate liquid biopsy analysis as a strong cancer biomarkers source with high potential for improving cancer patient’s evolution. Compared to classical biopsy, liquid biopsy is a minimal invasive procedure, and it allows the real-time monitoring of treatment response. Considering that lung cancer is the most common cause of cancer-associated death worldwide and that only 15–19% of the lung cancer patients survive five years after diagnosis, there is an important interest in improving its management. Like in other types of solid cancers, lung cancer could benefit from liquid biopsy through a simple peripheral blood sample as tumor-related biomarkers, such as circulating tumor cells (CTCs), cell-free nucleic acids (cfNA) [cell-free ribonucleic acid (cfRNA) and cell-free deoxyribonucleic acid (cfDNA)], exosomes and tumor-educated platelets (TEPs) may shed into circulation because of necrosis or in an active manner. More, the detection and analysis of these biomarkers could lead to a better understanding of oncological diseases like lung cancer. The better the tumor profile is established; the better management is possible. However, this approach has currently some limitations, such as low cfNA concentration or low count of CTCs that might be overcome by improving the actual methods and technologies. Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest 2022 2022-08-23 /pmc/articles/PMC9593132/ /pubmed/36074665 http://dx.doi.org/10.47162/RJME.63.1.02 Text en Copyright © 2020, Academy of Medical Sciences, Romanian Academy Publishing House, Bucharest https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open-access article distributed under the terms of a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License, which permits unrestricted use, adaptation, distribution and reproduction in any medium, non-commercially, provided the new creations are licensed under identical terms as the original work and the original work is properly cited.
spellingShingle Review
Irofei Zamfir, Maria-Anca
Buburuzan, Laura
Hudiţă, Ariana
Gălăţeanu, Bianca
Ginghină, Octav
Ion, Daniel
Motaş, Natalia
Ardeleanu, Carmen Maria
Costache, Marieta
Liquid biopsy in lung cancer management
title Liquid biopsy in lung cancer management
title_full Liquid biopsy in lung cancer management
title_fullStr Liquid biopsy in lung cancer management
title_full_unstemmed Liquid biopsy in lung cancer management
title_short Liquid biopsy in lung cancer management
title_sort liquid biopsy in lung cancer management
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9593132/
https://www.ncbi.nlm.nih.gov/pubmed/36074665
http://dx.doi.org/10.47162/RJME.63.1.02
work_keys_str_mv AT irofeizamfirmariaanca liquidbiopsyinlungcancermanagement
AT buburuzanlaura liquidbiopsyinlungcancermanagement
AT huditaariana liquidbiopsyinlungcancermanagement
AT galateanubianca liquidbiopsyinlungcancermanagement
AT ginghinaoctav liquidbiopsyinlungcancermanagement
AT iondaniel liquidbiopsyinlungcancermanagement
AT motasnatalia liquidbiopsyinlungcancermanagement
AT ardeleanucarmenmaria liquidbiopsyinlungcancermanagement
AT costachemarieta liquidbiopsyinlungcancermanagement